Industry News

Gilead Sciences and the World Health Organization have expanded their long-standing partnership to accelerate the elimination of visceral leishmaniasis (VL), also known as kala-azar, one of the world’s deadliest parasitic diseases.

Venus Remedies has achieved a major milestone after receiving Marketing Authorization from the Saudi Food and Drug Authority for its specialty oncology therapy Plerixafor. The approval marks the company’s first-ever global authorization for the drug and strengthens its growing focus on complex injectable therapies in regulated international markets.

Dr. Reddy’s Laboratories has announced the launch of Obeda® tablets, an oral semaglutide therapy for patients with diabetes in India. The launch marks another major step in the company’s expansion of its GLP-1 portfolio after recently introducing semaglutide injections in India and Canada.

India has once again delivered a setback to global pharmaceutical major AbbVie after the company lost its attempt to secure patent protection for its Hepatitis C therapy in the country, a move that could strengthen access to affordable generic medicines.

Japanese drugmaker Takeda Pharmaceutical Company is facing a major financial and legal challenge after a U.S. federal jury found the company liable in a high-profile antitrust lawsuit involving its constipation drug Amitiza (lubiprostone).

In a major step toward improving global pandemic preparedness, Swiss pharmaceutical giant Roche and the Medicines Patent Pool (MPP) have signed a voluntary licensing agreement to expand access to the influenza antiviral drug Xofluza (baloxavir marboxil) across 129 low and middle-income countries (LMICs).

Merck has announced encouraging Phase 3 results for its investigational cancer therapy sacituzumab tirumotecan (sac-TMT), offering new hope for patients with advanced or recurrent endometrial cancer who have limited treatment options after standard therapies fail.

The company revealed that the global TroFuse-005 clinical trial successfully achieved its two primary goals, improving overall survival (OS) and progression-free survival (PFS), when compared with conventional chemotherapy in previously treated patients.

Indian drug maker Alembic Pharmaceuticals has reported a strong financial performance for the fourth quarter of FY26, driven by steady growth in domestic formulations, robust US business expansion, and its strategic entry into the branded pharmaceuticals segment in the United States.

In a significant regulatory achievement, Alembic Pharmaceuticals has successfully cleared a Good Manufacturing Practices (GMP) inspection conducted by Brazil’s health regulatory authority, ANVISA, for its API-III manufacturing facility located at Karakhadi, Gujarat.

According to the company’s regulatory filing submitted to stock exchanges on May 15, 2026, the inspection was carried out from May 11 to May 15, 2026, and concluded without any observations.